In a patient with dyspnea and suspected systemic sclerosis, should a transthoracic echocardiogram be performed before a high‑resolution computed tomography (HRCT) of the chest?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Echo Should Be Performed First in Suspected Systemic Sclerosis with Dyspnea

In a patient with dyspnea and suspected systemic sclerosis, transthoracic echocardiogram should be performed before HRCT of the chest, as pulmonary arterial hypertension (PAH) is a life-threatening complication that requires immediate identification and carries higher mortality risk than interstitial lung disease alone.

Rationale for Echo-First Approach

The algorithmic approach should prioritize ruling out PAH because:

  • PAH is immediately life-threatening and requires urgent hemodynamic assessment and treatment initiation
  • Dyspnea is a cardinal symptom of PAH in systemic sclerosis patients
  • Echo has high specificity (75-96%) and positive predictive value for detecting pulmonary hypertension 1, 2
  • Echo can be performed rapidly and provides immediate actionable information about right heart function and estimated pulmonary pressures

Clinical Decision Algorithm

Step 1: Perform Transthoracic Echocardiography

Look for:

  • Estimated right ventricular systolic pressure (RVSP) >47 mmHg 1
  • Tricuspid regurgitation peak gradient (TRPG) >31 mmHg 3
  • Right ventricular dysfunction or enlargement
  • Pericardial effusion

Step 2: Interpret Echo Results

  • If RVSP >47 mmHg or TRPG >31 mmHg: Proceed directly to right heart catheterization for definitive PAH diagnosis 1, 3
  • If echo is normal or borderline: Proceed to HRCT to evaluate for interstitial lung disease

Step 3: Obtain HRCT

HRCT is essential for:

  • Detecting interstitial lung disease (ILD) patterns, particularly NSIP 4
  • Assessing extent of fibrosis using visual scoring or Goh's score 4
  • Identifying ground-glass opacities suggesting active alveolitis 5
  • Evaluating esophageal dilation (esophagopathy), which correlates with more severe vascular involvement 4

Important Caveats

Echo Limitations

  • Sensitivity is only 58-71% for detecting PAH 1, 3, meaning normal echo does not exclude PAH
  • Tricuspid regurgitation adequate for Doppler measurement is present in only 61% of patients 2
  • Echo may underestimate or overestimate pressures in individual patients 3
  • Right heart catheterization remains the gold standard for definitive PAH diagnosis 1, 3

When Both Are Needed Urgently

If clinical suspicion for both PAH and severe ILD is high (severe dyspnea, hypoxemia, very low DLCO <40%), both tests should be obtained rapidly and in parallel rather than sequentially.

Pulmonary Function Tests

PFTs should be obtained alongside imaging but cannot replace HRCT for ILD screening 6. However, the FVC/DLCO ratio >2.0 suggests PAH rather than ILD as the primary cause of dyspnea 1.

Why This Sequence Matters for Outcomes

Mortality risk: PAH in systemic sclerosis carries extremely high mortality if untreated, and early detection allows for initiation of PAH-specific therapies (phosphodiesterase-5 inhibitors, endothelin receptor antagonists) that improve survival 7.

Treatment implications: The presence of PAH versus ILD fundamentally changes management:

  • PAH requires vasodilator therapy and possible combination therapy
  • ILD requires immunosuppression (mycophenolate, rituximab, tocilizumab, or nintedanib) 5, 8
  • Some patients have both conditions requiring careful therapeutic balance

Morbidity considerations: Delayed PAH diagnosis leads to progressive right heart failure, whereas ILD typically progresses more slowly (though rapidly progressive ILD exists in certain subsets).

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.